Abstract：
Chronic kidney disease is a significant cause of morbidity and mortality worldwide. In recent years, Galectin-3 has been put forward as a potential biomarker of chronic kidney disease progression. This review aims to assess the clinical utility of Galectin-3 in various pathological processes leading up to chronic kidney disease such as diabetes and lupus nephritis. We conducted a systematic search on PubMed from inception to September 2023, using the search term (\"Galectin-3\" OR \"gal-3\") AND (\"renal\" OR \"kidney\"). Galectin-3 has been shown to be both pro-fibrotic and protective against renal fibrosis through various mechanisms such as apoptotic body clearance and modulation of the Wnt pathway. Studies have found associations between raised Galectin-3, incidence and progression of chronic kidney disease. In lupus nephritis, Galectin-3 may serve as a biomarker for lupus nephritis activity. Although Galectin-3 inhibits cystogenesis, there is no correlation between total kidney volume and Galectin-3 in polycystic kidney disease. The role of Galectin-3 in staging and prognostication of renal cell carcinoma is yet to be determined. Galectin-3 has potential in predicting chronic kidney disease progression, in combination with other biomarkers. However, more trials are required given that present studies demonstrate conflicting results on the relationship between Galectin-3 and clinical outcomes in chronic kidney disease patients of varying aetiologies.
摘要：
慢性肾脏病是世界范围内发病率和死亡率的重要原因。近年来,半乳糖凝集素-3已被提出作为慢性肾脏疾病进展的潜在生物标志物。这篇综述旨在评估Galectin-3在导致糖尿病和狼疮性肾炎等慢性肾脏疾病的各种病理过程中的临床应用。我们从成立到2023年9月对PubMed进行了系统搜索，使用搜索词（\"Galectin-3\"或\"gal-3\"）和（\"肾\"或\"肾\"）。已经显示半乳糖凝集素-3通过各种机制(例如凋亡体清除和Wnt途径的调节)既是促纤维化的又是针对肾纤维化的保护性的。研究发现半乳糖凝集素-3的升高与慢性肾脏疾病的发病率和进展之间存在关联。在狼疮性肾炎中，半乳糖凝集素-3可以作为狼疮性肾炎活动的生物标志物。虽然半乳糖凝集素-3抑制膀胱形成，在多囊肾疾病中，总肾脏体积与Galectin-3之间没有相关性。Galectin-3在肾细胞癌分期和预后中的作用尚待确定。半乳糖凝集素-3具有预测慢性肾病进展的潜力，与其他生物标志物相结合。然而,鉴于目前的研究表明,在不同病因的慢性肾脏病患者中,Galectin-3与临床结局之间的关系存在矛盾,因此需要更多的试验.
